Dynamic Technology Lab Private Ltd Makes New Investment in Haemonetics Corporation $HAE

Key Points

• Dynamic Technology Lab Private Ltd has invested approximately $468,000 in Haemonetics Corporation, acquiring 7,360 shares in the 1st quarter, as reported in its recent SEC filing.
• Haemonetics reported earnings of $1.10 per share in its latest quarter, exceeding analysts' expectations and revealing a revenue of $321.39 million, despite a year-over-year decline of 4.4%.
• Institutional investors own about 99.67% of Haemonetics' stock, with notable increases in holdings from Citigroup and MetLife Investment Management, reflecting strong institutional interest.

Dynamic Technology Lab Private Ltd purchased a new stake in Haemonetics Corporation (NYSE:HAE - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,360 shares of the medical instruments supplier's stock, valued at approximately $468,000.

Other large investors also recently modified their holdings of the company. Quarry LP increased its holdings in Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares during the period. University of Texas Texas AM Investment Management Co. bought a new position in Haemonetics in the 1st quarter valued at about $65,000. KBC Group NV lifted its position in Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after acquiring an additional 401 shares in the last quarter. Vise Technologies Inc. lifted its position in shares of Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock worth $221,000 after buying an additional 225 shares in the last quarter. Finally, CWC Advisors LLC. lifted its position in shares of Haemonetics by 7.4% during the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock worth $241,000 after buying an additional 212 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Performance

HAE stock traded down $0.39 on Tuesday, hitting $50.96. The company had a trading volume of 1,578,034 shares, compared to its average volume of 874,684. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04. Haemonetics Corporation has a 12-month low of $50.53 and a 12-month high of $94.99. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of 15.58, a P/E/G ratio of 0.95 and a beta of 0.39. The stock's 50-day simple moving average is $62.79 and its 200 day simple moving average is $65.18.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company's quarterly revenue was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, equities research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HAE. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price target on shares of Haemonetics in a report on Tuesday, May 20th. Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target for the company in a research report on Wednesday, July 9th. JPMorgan Chase & Co. restated a "neutral" rating and set a $62.00 price target (down from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Robert W. Baird assumed coverage on shares of Haemonetics in a report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price objective for the company. Finally, Baird R W raised shares of Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $78.78.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.